Clinical Trial Update: A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney Disease [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating different doses of BI 690517 alone or with empagliflozin in chronic kidney disease has completed, with results posted on 2024-08-29.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease

Drugs mentioned

• BI 690517
• Empagliflozin (empagliflozin)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Kidney Disease, Chronic | Phase 2 | Status: COMPLETED | Results posted: 2024-08-29